DarioHealth Corp. (DRIO)
0.69
-0.10 (-12.70%)
At close: Jan 14, 2025, 3:59 PM
0.70
1.30%
Pre-market Jan 15, 2025, 07:00 AM EST
undefined% (undefined)
| Bid | 0.68 |
| Market Cap | 26.39M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.93 |
| PE Ratio (ttm) | -0.74 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.7 |
| Volume | 16,450,473 |
| Avg. Volume (20D) | 186,924 |
| Open | 0.81 |
| Previous Close | 0.79 |
| Day's Range | 0.65 - 1.38 |
| 52-Week Range | 0.63 - 2.60 |
| Beta | undefined |
About DRIO
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chron...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Mar 14, 2016
Employees 276
Stock Exchange NASDAQ
Ticker Symbol DRIO
Website https://www.mydario.com
Analyst Forecast
According to 1 analyst ratings, the average rating for DRIO stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 478.87% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
DarioHealth Corp. is scheduled to release its earnings on Mar 27, 2025,
before market opens.
Analysts project revenue of $7.41M, reflecting a 104.92% YoY growth and earnings per share of -0.16, making a -60.98% decrease YoY.
Analysts project revenue of $7.41M, reflecting a 104.92% YoY growth and earnings per share of -0.16, making a -60.98% decrease YoY.
1 month ago ·
Source
+6.4%
DarioHealth shares are trading higher after the co...
Unlock content with
Pro Subscription
